ILAE Classification of Seizures and Epilepsies: An Update for the Pediatrician

The dysregulation of miRNAs in epilepsy and their regulatory role in inflammation and apoptosis

Epilepsy is a neurological disorder that impacts millions of people worldwide, and it is characterized by the occurrence of recurrent seizures. The pathogenesis of epilepsy is complex, involving dysregulation of various genes and signaling pathways. MicroRNAs (miRNAs) are a group of small non-coding RNAs that play a vital role in the regulation of gene expression. They have been found to be involved in the pathogenesis of epilepsy, acting as key regulators of neuronal excitability and synaptic plasticity. In recent years, there has been a growing interest in exploring the miRNA regulatory network in epilepsy. This review summarizes the current knowledge of the regulatory miRNAs involved in inflammation and apoptosis in epilepsy and discusses its potential as a new avenue for developing targeted therapies for the treatment of epilepsy.

Current Classification of Seizures and Epilepsies: Scope, Limitations and Recommendations for Future Action

The classification of seizures and epilepsies by the International League Against Epilepsy (ILAE), 2017 is the most recent classification model which aimed to simplify terminologies that patients and their caregivers can easily understand, identify seizures that have both focal and generalized onset and incorporate missing seizures. We have exhaustively reviewed the studies, discussed its scope, outlined its limitations and gave recommendations that could help in forming subsequent reviews. We have also described the terminologies that have been replaced, redefined or removed to have a clear view of the previous and the current classification models. We have recommended the use of multidimensional classification model which incorporated the clinical semiology, disease location, etiology and associated comorbidities. The benefits of this model is for prompt diagnosis which will results into early management and then better patient outcomes. It would also have a profound effects on the kind of treatment patients might receive especially in developing countries where there are scarcity of the diagnostic techniques. Overall, in this study we have reviewed the current study on seizures and epilepsy classification model by ILAE, 2017 to clarify the descriptions and coverage, outlined some limitations and suggested recommendations.

Clinico-etiological Profile and Developmental Status of Infants Aged 1-24 months with Epilepsy

OBJECTIVE

To study the clinico-etiological profile of epilepsy in children aged 1-24 mo attending a tertiary-care public hospital.

METHODS

All infants aged 1-24 mo with epilepsy (as per International League Against Epilepsy, 2014) presenting between April 2016 and March 2017 were enrolled. Detailed history and examination were done in all children, and developmental assessment was done using Developmental Assessment Scale for Indian Infants (DASII). Electroencephalography and neuroimaging (CT/MRI) were done for all subjects.

RESULTS

Sixty children (39 males) were consecutively enrolled after informed written consent. The mean (SD) age at seizure onset was 4.3 (4.14) mo. Perinatal asphyxia (45%) and malformations of cortical development (18.3%) were the commonest etiologies. Neurological examination was abnormal in 68.3%, and a neuroimaging abnormality was present in 76% of children. Fifteen patients (25%) had West syndrome, which was symptomatic in the majority (73.3%). Developmental delay (DQ < 70) was the commonest co-morbidity (81.7%); 28.3% had profound delay. Odds of having developmental delay were 13-times higher in those with an abnormal neurological examination [OR 13.5 (2.82-64.67), P = 0.001], and nearly 9-times higher with abnormal neuroimaging [OR 8.9 (2.11-37.9), P = 0.003].

CONCLUSIONS

Epilepsy in children <2 y is symptomatic in the majority, with sequelae of birth asphyxia as the commonest etiology. High prevalence of co-morbid developmental delay underscores the need for routine evaluation and early intervention in all high-risk infants.